Covalently linked antigen-antibody conjugates

Patent metadata

Field	Value
Publication number	US-10517945-B2
Application number	US-201414577084-A
Country	US
Kind code	B2
Filing date	Dec 19, 2014
Priority date	Jul 4, 2012
Publication date	Dec 31, 2019
Grant date	Dec 31, 2019

Abstract

Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.

First claim

What is claimed is:

1. An isolated antibody that binds to biotin, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 57; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 58; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 59; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 61; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:62; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 63.

2. The antibody of claim 1 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 60 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 64.

3. An isolated antibody that binds to theophylline, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 89; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 90; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 91; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 93; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:94; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 95.

4. The antibody of claim 3 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 92 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 96.

5. An isolated antibody that binds to fluorescein, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 105; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 106; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 107; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 109; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:110; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 111.

6. The antibody of claim 5 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 108 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 112.

7. An isolated antibody that binds to digoxigenin, wherein the antibody comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 25; a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 26; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 27; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:30; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 31.

8. The antibody of claim 7 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO: 28 and a variable light chain comprising the amino acid sequence of SEQ ID NO: 32.

9. The antibody of claim 1 , wherein the antibody is a multispecific antibody comprising a first binding site that binds to biotin and a second binding site that specifically binds to a cell surface marker.

10. The antibody of claim 1 , wherein the antibody is humanized.

11. The antibody of claim 3 , wherein the antibody is a multispecific antibody comprising a first binding site that binds to theophylline and a second binding site that specifically binds to a cell surface marker.

12. The antibody of claim 3 , wherein the antibody is humanized.

13. The antibody of claim 5 , wherein the antibody is a multispecific antibody comprising a first binding site that binds to fluorescein and a second binding site that specifically binds to a cell surface marker.

14. The antibody of claim 5 , wherein the antibody is humanized.

15. The antibody of claim 7 , wherein the antibody is a multispecific antibody comprising a first binding site that binds to digoxigenin and a second binding site that specifically binds to a cell surface marker.

16. The antibody of claim 7 , wherein the antibody is humanized.

Assignees

• Hoffmann La Roche

Inventors

• Benz Joerg
• Brinkmann Ulrich
• Dengl Stefan
• Dziadek Sebastian
• Georges Guy
• Grote Michael
• Haas Alexander
• Hoffmann Eike

Classifications

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title